French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults

F Amatore, A-P Villani, M Tauber, M Viguier, B Guillot, Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), F Amatore, A-P Villani, M Tauber, M Viguier, B Guillot, Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie)

Abstract

These guidelines were developed by the psoriasis research group of the French Society of Dermatology with the aim of providing updated decision-making algorithms for the systemic treatment of adult patients with moderate-to-severe psoriasis. Our algorithms were generated after rigorous evaluation of existing guidelines on the treatment of psoriasis and of publications concerning new systemic treatments, not yet incorporated into existing guidelines. A total of nine existing guidelines and 53 publications related to new systemic treatments were found to meet our criteria for use in the generation of the algorithms. We have proposed two new algorithms to assess therapeutic responses, both of which incorporate emerging criteria for evaluating treatment goals. Updated therapeutic strategy algorithms, incorporating both established and new systemic therapies, were also generated for the treatment of plaque psoriasis and psoriatic arthritis, together with recommendations for the treatment of particular forms of psoriasis and treatment of patients with comorbidities.

© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Figures

Figure 1
Figure 1
Treatment goals in plaque psoriasis. (a, b) Updated decision algorithms considered as acceptable by the current working group. DLQI, dermatology life quality index; PASI, psoriasis area severity index; PGA, physician global assessment.
Figure 2
Figure 2
Treatment algorithm for patients suffering from plaque psoriasis without comorbidities. CSA, cyclosporin; MTX, methotrexate; NBUVB, Narrowband UVB; PUVA, psoralen UVA; re‐PUVA, retinoid psoralen UVA.
Figure 3
Figure 3
Psoriatic arthritis treatment algorithm – adapted from the EULAR, GRAPPA and UK NICE guidelines.6, 9, 19, 20 APR, apremilast; ADA, adalimumab; CSA, cyclosporin; DMARD, disease‐modifying anti‐rheumatic drugs; MTX, methotrexate; NSAIDs, nonsteroidal anti‐inflammatory drugs; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitors; USTK, ustekinumab.

References

    1. Fervers B, Burgers JS, Voellinger R et al Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation. BMJ Qual Saf 2011; 20: 228–236.
    1. Brouwers MC, Kho ME, Browman GP et al AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010; 182: E839–E842.
    1. Atkins D, Best D, Briss PA et al GRADE Working Group . Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
    1. HAS (Haute autorité de santé) . Recommandations pour la Pratique Clinique. Haute autorité de santé, Saint‐Denis, 2016.
    1. Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS. Combining biologic therapies with other systemic treatments in psoriasis: evidence‐based, best‐practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol 2015; 151: 432–438.
    1. Coates LC, Kavanaugh A, Mease PJ et al Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 2016; 68: 1060–1071.
    1. Coates LC, Tillett W, Chandler D et al The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology (Oxford) 2013; 52: 1754–1757.
    1. Crowley JJ, Weinberg JM, Wu JJ et al Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol 2015; 151: 87–94.
    1. Gossec L, Smolen JS, Ramiro S et al European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016; 75: 499–510.
    1. Langley RG, Saurat JH, Reich K. Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. J Eur Acad Dermatol Venereol 2012; 26: 373–381.
    1. Nast A, Boehncke WH, Mrowietz U et al German S3‐guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2012; 304: 87–113.
    1. Nast A, Gisondi P, Ormerod AD et al European S3‐Guidelines on the systemic treatment of psoriasis vulgaris–Update 2015–Short version–EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015; 29: 2277–2294.
    1. Samarasekera E, Sawyer L, Parnham J, Smith CH. Assessment and management of psoriasis: summary of NICE guidance. BMJ 2012; 345: 1373–1378.
    1. Smith CH, Jabbar‐Lopez ZK, Yiu ZZ et al British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol 2017; 177: 628–636.
    1. Mrowietz U, Kragballe K, Reich K et al Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1–10.
    1. Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol 2015; 29: 645–648.
    1. Torres T, Puig L. Treatment goals for psoriasis: should PASI 90 become the standard of care? Actas Dermosifiliogr 2015; 106: 155–157.
    1. Agence Nationale de Sécurité du Médicament (ANSM) . État des lieux sur les médicaments biosimilaires – Mai 2016. URL (last accessed: 30 November 2018).
    1. Gossec L, Smolen JS, Gaujoux‐Viala C et al European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71: 4–12.
    1. Ramiro S, Smolen JS, Landewe R et al Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2016; 75: 490–498.
    1. Gossec L, Coates LC, de Wit M et al Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol 2016; 12: 743–750.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться